Nintedanib - Boehringer Ingelheim
At a glance
- Drug Originator Boehringer Ingelheim
- Drug Class Acetamides; Antifibrotics; Antineoplastics; Esters; Indoles; Piperazines; Skin disorder therapies; Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Lymphocyte specific protein tyrosine kinase p56(lck) inhibitors; Lyn protein-tyrosine kinase inhibitors; Platelet-derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Src-family kinase inhibitors; Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists; Vascular endothelial growth factor receptor-3 antagonists
- USA Patent Applicants BOEHRINGER INGELHEIM
- USA Patents 6
- NDAs 1
- International Patents 197
- Patent Applications 209
Table of Contents

Disclaimer